Enfortumab vedotin - Agensys/Seattle Genetics

Drug Profile

Enfortumab vedotin - Agensys/Seattle Genetics

Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab; Enfortumab vedotin

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agensys; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Urogenital cancer

Most Recent Events

  • 27 Jul 2018 Phase-III clinical trials in Urogenital cancer in Japan, Europe, Asia (IV) (Astellas Pharma pipeline, July 2018)
  • 09 Jul 2018 Seattle Genetics and Astellas complete enrolment in the phase II EV-201 trial for Urogenital cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA and Japan (NCT03219333)
  • 03 Jun 2018 Updated efficacy and adverse events data from a phase I trial in Urogenital cancer presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top